arrow
C

Chiara Ricci

University College Cork
H指数:43
被引数:7,009

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience

关于免疫治疗时代接受多模式治疗的晚期胆道癌患者的初步报告:一项真实世界多中心经验

2026-03-190
OA
A new intestinal ultrasound score to assess post-operative recurrence in Crohn's disease: the PROSPER-IUS

一种用于评估克罗恩病术后复发的新的肠道超声评分:PROSPER-IUS

2026-01-010
PRE
Risk of relapse and retreatment success after vedolizumab discontinuation in patients with IBD in long-standing remission: a retrospective study from the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)

在长期缓解的炎症性肠病患者中停用 Vedolizumab 后的复发风险及再治疗成功率:意大利炎症性肠病研究组(IG-IBD)的回顾性研究

2026-01-010
PRE
Impact of transforming growth factor-β2 enriched food for special medical purposes on nutritional status, microbiota and clinical outcomes after allogeneic hematopoietic stem cell transplantation: prospective analysis of 192 consecutive patients

转化生长因子-β2强化特殊医学用途配方食品对异基因造血干细胞移植后患者营养状况、肠道菌群及临床结局的影响:192例连续患者的前瞻性分析

2025-06-300
PRE
Psychological and Clinical Factors Mediate Post-COVID-19 Irritable Bowel Syndrome

心理和临床因素介导后COVID-19肠易激综合征

2025-05-150
OAAI
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study

Vedolizumab在炎症性肠病中的真实世界结局及其机器学习预测——IG-IBD LIVE研究

2025-05-120
PRE
Long-Term Impact of COVID-19 on Disorders of Gut-Brain Interaction: Incidence, Symptom Burden, and Psychological Comorbidities
2025-03-211
OAAI
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)
2024-09-012
PRE
Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis
2024-02-010
PRE
Autoimmune polyglandular syndrome type 4: experience from a single reference center

4型自身免疫性多腺体综合征: 来自单个参考中心的经验

2023-10-233
OAAI